Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 8, pp 351–362 | Cite as

Ertugliflozin in type 2 diabetes: a profile of its use

  • Lesley J. ScottEmail author
Adis Drug Q&A
  • 220 Downloads

Abstract

Oral ertugliflozin (Steglatro™), a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, is approved in numerous countries as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes (T2D), either as monotherapy or add-on therapy to other antihyperglycaemic agents; specific indications may vary between individual countries. In numerous well-designed VERTIS trials and extension studies in adults with inadequately controlled T2D, ertugliflozin monotherapy, initial combination therapy to sitagliptin and add-on therapy to metformin or to metformin plus sitagliptin consistently provided effective and durable glycaemic control, and reduced bodyweight and blood pressure. Ertugliflozin is generally well tolerated, with a good benefit/risk profile. The availability of ertugliflozin/metformin (Segluromet™) and ertugliflozin/sitagliptin (Steglujan™) fixed-dose combinations (FDCs) may potentially improve compliance/adherence in patients requiring intensification of antihyperglycaemic treatment with combination therapy to achieve adequate glycaemic control. Given the proven benefits of other SGLT2 inhibitors on cardiovascular (CV) and renal outcomes, results from the ongoing VERTIS CV outcome trial are awaited with interest.

Notes

Acknowledgements

The manuscript was reviewed by: A. Antonelli, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; G. D. Dimitriadis, 2nd Department of Internal Medicine, Research Institute and Diabetes Center, Athens University Medical School, Attikon University Hospital, Athens, Greece. During the peer review process, Merck Sharp & Dohme B.V. and Pfizer Inc., the marketing-authorization holders of ertugliflozin, were offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Lesley Scott is an employee of Adis International Ltd./Springer Nature, is responsible for the article content and declares no conflicts of interest.

References

  1. 1.
    International Diabetes Federation. Diabetes: facts and figures. 2017. http://www.idf.org/. Accessed 6 May 2019.
  2. 2.
    Davies MJ, D’Alessio DA, Fradkin J, Management of hyperglycemia in type 2 diabetes, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;2018(41):2669–701.CrossRefGoogle Scholar
  3. 3.
    American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1):S103–23.CrossRefGoogle Scholar
  4. 4.
    American Diabetes Association. Glycemic targets: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1):S61–70.CrossRefGoogle Scholar
  5. 5.
    American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1):S90–102.CrossRefGoogle Scholar
  6. 6.
    Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement of the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2019 Executive Summary. Endocr Pract. 2019;25(1):69–100.CrossRefGoogle Scholar
  7. 7.
    Hsia DS, Grove O, Cefalu WT. An update on SGLT2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73–9.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Yehya A, Sadhu AR. New therapeutic strategies for type 2 diabetes. Methodist Debakey Cardiovasc J. 2018;14(4):281–8.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–9.CrossRefGoogle Scholar
  10. 10.
    Cruz JE, Ahuja T, Bridgeman MB. Renal and cardiac implications of sodium glucose cotransporter 2 (SGLT2) inhibitors: the state of the science. Ann Pharmacother. 2018;52(12):1238–49.CrossRefGoogle Scholar
  11. 11.
    Steglatro (ertugliflozin) 5 and 15 mg film-coated tablets: EU summary of product characteristics. Haarlem: Merck Sharp & Dohme B.V.; 2018.Google Scholar
  12. 12.
    Steglatro™ (ertugliflozin) tablet, film coated: US prescribing information. Whitehouse Station (NJ): Merck & Co Inc.; 2018.Google Scholar
  13. 13.
    Segluromet™ (ertugliflozin and metformin hydrochloride) tablet, film coated: US prescribing information. Whitehouse Station (NJ): Merck & Co Inc.; 2018.Google Scholar
  14. 14.
    Segluromet (ertugliflozin + metformin hydrochloride) 2.5 mg/850 mg, 2.5 mg/1,000 mg, 7.5 mg/850 mg and 7.5 mg/1,000 mg film-coated tablets: EU summary of product characteristics. Haarlem: Merck Sharp & Dohme B.V.; 2018.Google Scholar
  15. 15.
    Steglujan™ (ertugliflozin and sitagliptin) tablet, film coated: US prescribing information. Whitehouse Station (NJ): Merck & Co Inc.; 2018.Google Scholar
  16. 16.
    Steglujan (ertugliflozin + sitagliptin) 5 mg/100 mg and 15 mg/100 mg film-coated tablets: EU summary of product characteristics. Haarlem: Merck Sharp & Dohme B.V.; 2018.Google Scholar
  17. 17.
    Nucci G, Le V, Sweeney K, et al. Single- and multiple-dose pharmacokinetics and pharmacodynamics of ertugliflozin, an oral selective inhibitor of SGLT2, in healthy subjects [abstract no. PII-106]. Clin Pharmacol Ther. 2018;103(Suppl 1):S83.Google Scholar
  18. 18.
    Amin NB, Wang X, Mitchell JR, et al. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17(8):805–8.CrossRefGoogle Scholar
  19. 19.
    Amin NB, Wang X, Jain SM, et al. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17(6):591–8.CrossRefGoogle Scholar
  20. 20.
    Sahasrabudhe V, Saur D, Matschke K, et al. A phase 1, randomized, placebo- and active-controlled crossover study to determine the effect of single-dose ertugliflozin on QTc interval in healthy volunteers. Clin Pharmacol Drug Dev. 2018;20(5):512–23.Google Scholar
  21. 21.
    Sahasrabudhe V, Fediuk DJ, Matschke K, et al. Effect of food on the pharmacokinetics of ertugliflozin and its fixed-dose combinations ertugliflozin/sitagliptin and ertugliflozin/metformin. Clin Pharmacol Drug Dev. 2018.  https://doi.org/10.1002/cpdd.629.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013;41(2):445–56.CrossRefGoogle Scholar
  23. 23.
    Sahasrabudhe V, Terra SG, Hickman A, et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017;57(11):1432–43.CrossRefGoogle Scholar
  24. 24.
    Sahasrabudhe V, Terra SG, Hickman A, et al. Pharmacokinetics of single-dose ertugliflozin in patients with hepatic impairment. Clin Ther. 2018;40(10):1701–10.CrossRefGoogle Scholar
  25. 25.
    Dawra V, Liang Y, Wei H, et al. Bioequivalence of ertugliflozin/metformin fixed-dose combination tablets and co-administration of respective strengths of individual components. Clin Pharmacol Drug Dev. 2019.  https://doi.org/10.1002/cpdd.703.CrossRefPubMedGoogle Scholar
  26. 26.
    Fediuk DJ, Matschke K, Liang Y, et al. Bioequivalence of ertugliflozin/sitagliptin fixed-dose combination tablets and coadministration of respective strengths of individual components. Clin Pharmacol Drug Dev. 2019.  https://doi.org/10.1002/cpdd.722.CrossRefPubMedGoogle Scholar
  27. 27.
    Dawra VK, Liang Y, Shi H, et al. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects. Int J Clin Pharmacol Ther. 2019;57(4):207–16.CrossRefGoogle Scholar
  28. 28.
    Dawra VK, Sahasrabudhe V, Liang Y, et al. Effect of rifampin on the pharmacokinetics of ertugliflozin in healthy subjects. Clin Ther. 2016;40(9):1538–47.CrossRefGoogle Scholar
  29. 29.
    Dawra VK, Cutler DL, Zhou S, et al. Assessment of the drug interaction potential of ertugliflozin with sitagliptin, metformin, glimepiride, or simvastatin in healthy subjects. Clin Pharmacol Drug Dev. 2018;8(3):314–25.CrossRefGoogle Scholar
  30. 30.
    Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721–8.CrossRefGoogle Scholar
  31. 31.
    Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2017;20(3):520–9.CrossRefGoogle Scholar
  32. 32.
    Gallo S, Charbonnel B, Goldman A, et al. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab. 2019.  https://doi.org/10.1111/dom.13631.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Ji L, Liu Y, Miao H, et al. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes Metab. 2019;21(6):1474–82.CrossRefGoogle Scholar
  34. 34.
    Hollander P, Liu J, Hill J, et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther. 2017;9(1):193–207.CrossRefGoogle Scholar
  35. 35.
    Hollander P, Hill J, Johnson J, et al. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin. 2019.  https://doi.org/10.1080/03007995.2019.1583450.CrossRefPubMedGoogle Scholar
  36. 36.
    Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111–20.CrossRefGoogle Scholar
  37. 37.
    Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530–40.CrossRefGoogle Scholar
  38. 38.
    Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther. 2018;9:253–68.CrossRefGoogle Scholar
  39. 39.
    Aronson R, Frias J, Goldman A, et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab. 2018;20(6):1453–60.CrossRefGoogle Scholar
  40. 40.
    Liu J, Pong A, Gallo S, et al. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Cardiovasc Diabetol. 2019;18(1):59.CrossRefGoogle Scholar
  41. 41.
    Liu J, Tarasenko L, Terra SG, et al. Efficacy of ertugliflozin monotherapy or combination therapy in patients with type 2 diabetes: a pooled analysis of placebo-controlled studies. Diab Vasc Dis Res. 2019.  https://doi.org/10.1177/1479164119842513.CrossRefPubMedGoogle Scholar
  42. 42.
    Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9(1):49–66.CrossRefGoogle Scholar
  43. 43.
    Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11–23.CrossRefGoogle Scholar
  44. 44.
    Patel SM, Hickman MA, Frederich R, et al. Evaluation of osmotic diuresis and volume depletion events in patients with type 2 diabetes mellitus (T2DM) receiving ertugliflozin [abstract no. 1169-P]. Diabetes. 2018;67(Suppl 1):A313.Google Scholar
  45. 45.
    Patel SM, Hickman MA, Frederich R, et al. Assessment of adverse renal effects in patients with type 2 diabetes mellitus (T2DM) receiving ertugliflozin [abstract no. 1168-P]. Diabetes. 2018;67(Suppl. 1):A313.Google Scholar
  46. 46.
    Hickman MA, Patel S, Lauring B, et al. Incidence of urinary tract infections in patients with type 2 diabetes receiving ertugliflozin, placebo or active comparator [abstract no. 630]. Diabetologia. 2018;61(Suppl 1):S306.Google Scholar
  47. 47.
    Hickman MA, Frederich R, Patel SM, et al. Evaluation of fractures, bone mineral density (BMD), and bone biomarkers in patients with type 2 diabetes mellitus (T2DM) receiving ertugliflozin [abstract no. 1145-P]. Diabetes. 2018;67(Suppl 1):A307.Google Scholar
  48. 48.
    National Institute for Health and Care Excellence. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes. 2019. http://www.nice.org.uk/guidance/ta572. Accessed 5 May 2019.
  49. 49.
    McNeill AM, Davies G, Kruger E, et al. Ertugliflozin compared to other anti-hyperglycemic agents as monotherapy and add-on therapy in type 2 diabetes: a systematic literature review and network meta-analysis. Diabetes Ther. 2019;1:1.  https://doi.org/10.1007/s13300-019-0566-x.CrossRefGoogle Scholar
  50. 50.
    Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations